Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

RCT (n=127) found a significantly lower decline in FVC for pirfenidone vs placebo (p=0.043). The estimated difference in FVC % predicted at week 48 was 3.53% Results should be interpreted with caution however as the study was terminated early owing to slow recruitment.

SPS commentary:

Four lung diseases were investigated in this study, namely collagen or vascular diseases (ie, connective tissue disease-associated interstitial lung diseases), fibrotic non-specific interstitial pneumonia, chronic hypersensitivity pneumonitis, or asbestos-induced lung fibrosis.

The Lancet Respiratory Medicine